Novocure Ltd Ord Sh Down 5.06% To $70.22 After Earnings Miss

Novocure Ltd Ord Sh (NVCR) said before open Thursday that it lost $0.23 per share in quarter two 2022.

On the revenue line, the company reported $140.9 million, beating estimates by $5.9 million.

In the same quarter a year ago, the company lost $0.14 per share on revenue of $133.5 million.

The stock is down 5.06% to $70.22 after the report.

Novocure Ltd Ord Sh's earnings expanded faster than revenues, signaling widening profit margins.

The average recommendation from Wall Street analysts was a Hold which may get revised based on this new data.

Trading in the five days leading up to the report earned Novocure Ltd Ord Sh a Bullish Sentiment Rank from InvestorsObserver.

Novocure Ltd Ord Sh has performed a little below average during the past few months. Before the report, Novocure Ltd Ord Sh received a Long-Term Technical Rank by InvestorsObserver of 31, putting it in the bottom half of stocks. The firm was recently trading at a 52-week low of $56.39 on June 16, 2022 and set a 52-week high on July 28, 2021 at $185.91.

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.